These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 26317919)

  • 1. Dissecting Pulmonary Large-Cell Carcinoma by Targeted Next Generation Sequencing of Several Cancer Genes Pushes Genotypic-Phenotypic Correlations to Emerge.
    Pelosi G; Fabbri A; Papotti M; Rossi G; Cavazza A; Righi L; Tamborini E; Perrone F; Settanni G; Busico A; Testi MA; Maisonneuve P; De Braud F; Garassino M; Valeri B; Sonzogni A; Pastorino U
    J Thorac Oncol; 2015 Nov; 10(11):1560-9. PubMed ID: 26317919
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Next-Generation Sequencing of a Cohort of Pulmonary Large Cell Carcinomas Reclassified by World Health Organization 2015 Criteria.
    Driver BR; Portier BP; Mody DR; Deavers M; Bernicker EH; Kim MP; Teh BS; Santacruz JF; Kopas L; Munden RF; Cagle PT
    Arch Pathol Lab Med; 2016 Apr; 140(4):312-7. PubMed ID: 26430808
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ΔNp63 (p40) and thyroid transcription factor-1 immunoreactivity on small biopsies or cellblocks for typing non-small cell lung cancer: a novel two-hit, sparing-material approach.
    Pelosi G; Fabbri A; Bianchi F; Maisonneuve P; Rossi G; Barbareschi M; Graziano P; Cavazza A; Rekhtman N; Pastorino U; Scanagatta P; Papotti M
    J Thorac Oncol; 2012 Feb; 7(2):281-90. PubMed ID: 22071786
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pulmonary large cell carcinoma lacking squamous differentiation is clinicopathologically indistinguishable from solid-subtype adenocarcinoma.
    Hwang DH; Szeto DP; Perry AS; Bruce JL; Sholl LM
    Arch Pathol Lab Med; 2014 May; 138(5):626-35. PubMed ID: 23738762
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Distribution of KRAS, DDR2, and TP53 gene mutations in lung cancer: An analysis of Iranian patients.
    Fathi Z; Mousavi SAJ; Roudi R; Ghazi F
    PLoS One; 2018; 13(7):e0200633. PubMed ID: 30048458
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Landscape of Actionable Molecular Alterations in Immunomarker-Defined Large-Cell Carcinoma of the Lung.
    Chan AW; Chau SL; Tong JH; Chow C; Kwan JSH; Chung LY; Lung RW; Tong CY; Tin EK; Law PP; Law WT; Ng CSH; Wan IYP; Mok TSK; To KF
    J Thorac Oncol; 2019 Jul; 14(7):1213-1222. PubMed ID: 30978501
    [TBL] [Abstract][Full Text] [Related]  

  • 7. TP53, NOTCH2, and STK11 Mutations in a Rare Tumor of non-Small Cell Lung Carcinoma with Diffuse Coexpression of TTF1 and p40 in the Same Tumor Cells.
    Guo X; Dong L; Liu H; Chen X
    Int J Surg Pathol; 2023 Sep; 31(6):1041-1047. PubMed ID: 36253711
    [No Abstract]   [Full Text] [Related]  

  • 8. Defective expression of transforming growth factor beta type II receptor (TGFBR2) in the large cell variant of non-small cell lung carcinoma.
    Xu JB; Bao Y; Liu X; Liu Y; Huang S; Wang JC
    Lung Cancer; 2007 Oct; 58(1):36-43. PubMed ID: 17566598
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Large cell carcinoma of the lung: a tumor in search of an author. A clinically oriented critical reappraisal.
    Pelosi G; Barbareschi M; Cavazza A; Graziano P; Rossi G; Papotti M
    Lung Cancer; 2015 Mar; 87(3):226-31. PubMed ID: 25620799
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ΔNp63 (p40) distribution inside lung cancer: a driver biomarker approach to tumor characterization.
    Pelosi G; Rossi G; Cavazza A; Righi L; Maisonneuve P; Barbareschi M; Graziano P; Pastorino U; Garassino M; de Braud F; Papotti M
    Int J Surg Pathol; 2013 Jun; 21(3):229-39. PubMed ID: 23486764
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Does immunohistochemistry affect response to therapy and survival of inoperable non-small cell lung carcinoma patients? A survey of 145 stage III-IV consecutive cases.
    Pelosi G; Haspinger ER; Bimbatti M; Leone G; Paolini B; Fabbri A; Tamborini E; Perrone F; Testi A; Garassino M; Maisonneuve P; de Braud F; Pilotti S; Pastorino U
    Int J Surg Pathol; 2014 Apr; 22(2):136-48. PubMed ID: 24326823
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Clinicopathologic features and genetic profile of the redefined large cell lung carcinoma].
    Hou LK; Zhang LP; Zhang W; Huang Y; Wu W; Dong ZW; Wu CY
    Zhonghua Bing Li Xue Za Zhi; 2017 May; 46(5):298-302. PubMed ID: 28468033
    [No Abstract]   [Full Text] [Related]  

  • 13. Clinical next-generation sequencing successfully applied to fine-needle aspirations of pulmonary and pancreatic neoplasms.
    Young G; Wang K; He J; Otto G; Hawryluk M; Zwirco Z; Brennan T; Nahas M; Donahue A; Yelensky R; Lipson D; Sheehan CE; Boguniewicz AB; Stephens PJ; Miller VA; Ross JS
    Cancer Cytopathol; 2013 Dec; 121(12):688-94. PubMed ID: 23893923
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular genetic alterations in thyroid transcription factor 1-negative lung adenocarcinoma in cytology specimens: A subset with aggressive behavior and a poor prognosis.
    Rodriguez EF; VandenBussche CJ; Chowsilpa S; Maleki Z
    Cancer Cytopathol; 2018 Oct; 126(10):853-859. PubMed ID: 30199148
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Primary Pulmonary Mucoepidermoid Carcinoma: Histopathological and Moleculargenetic Studies of 26 Cases.
    Huo Z; Wu H; Li J; Li S; Wu S; Liu Y; Luo Y; Cao J; Zeng X; Liang Z
    PLoS One; 2015; 10(11):e0143169. PubMed ID: 26575266
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Large cell carcinoma of the lung: clinically oriented classification integrating immunohistochemistry and molecular biology.
    Rossi G; Mengoli MC; Cavazza A; Nicoli D; Barbareschi M; Cantaloni C; Papotti M; Tironi A; Graziano P; Paci M; Stefani A; Migaldi M; Sartori G; Pelosi G
    Virchows Arch; 2014 Jan; 464(1):61-8. PubMed ID: 24221342
    [TBL] [Abstract][Full Text] [Related]  

  • 17. SMARCA4-deficient pulmonary adenocarcinoma: clinicopathological, immunohistochemical, and molecular characteristics of a novel aggressive neoplasm with a consistent TTF1
    Agaimy A; Fuchs F; Moskalev EA; Sirbu H; Hartmann A; Haller F
    Virchows Arch; 2017 Nov; 471(5):599-609. PubMed ID: 28555282
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mutational and gene fusion analyses of primary large cell and large cell neuroendocrine lung cancer.
    Karlsson A; Brunnström H; Lindquist KE; Jirström K; Jönsson M; Rosengren F; Reuterswärd C; Cirenajwis H; Borg Å; Jönsson P; Planck M; Jönsson G; Staaf J
    Oncotarget; 2015 Sep; 6(26):22028-37. PubMed ID: 26124082
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Distinct profile of driver mutations and clinical features in immunomarker-defined subsets of pulmonary large-cell carcinoma.
    Rekhtman N; Tafe LJ; Chaft JE; Wang L; Arcila ME; Colanta A; Moreira AL; Zakowski MF; Travis WD; Sima CS; Kris MG; Ladanyi M
    Mod Pathol; 2013 Apr; 26(4):511-22. PubMed ID: 23196793
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Histomolecular profiling of pleomorphic, spindle cell, and giant cell carcinoma of the lung for targeted therapies.
    Forest F; Yvorel V; Karpathiou G; Stachowicz ML; Vergnon JM; Fournel P; Tiffet O; Trombert B; Péoc'h M
    Hum Pathol; 2016 Mar; 49():99-106. PubMed ID: 26826416
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.